Akari Therapeutics plc ADR (0.01 USD) vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| AKTX | LLY | |
|---|---|---|
| Market Cap | $17.83 million | $1.03 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | $-30,960,000 | $26.71 billion |
LLY leads on 2 of 2 size & scale factors.
Valuation
| AKTX | LLY | |
|---|---|---|
| P/E Ratio | — | 38.70 |
| Price / Book | 0.96 | 30.33 |
| Price / Sales | — | 12.90 |
AKTX leads on 1 of 1 valuation factors.
Profitability
| AKTX | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | -166.50% | 78.84% |
LLY leads on 1 of 1 profitability factors.
Dividend
| AKTX | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
| Payout Ratio | — | 23.23 |
AKTX and LLY split the dividend factors evenly.
Risk & Sentiment
| AKTX | LLY | |
|---|---|---|
| Short Interest | 30.21% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: AKTX overview, AKTX financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.